The search engine found new reagents in the following categories.
SARS-CoV-2
|
NRH-21756
|
Pooled Human Serum Sample, Novavax Vaccine (1.0 mL)
|
BEI Level 2
|
June
2022
|
|
NR-56132
|
Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293F Cells
SARS-Related Coronavirus 2
|
BEI Level 1
|
June
2022
|
|
NR-56134
|
Spike Glycoprotein (Stabilized) from Human Coronavirus NL63, with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells
Human Coronavirus
|
BEI Level 1
|
June
2022
|
|
NR-56519
|
SARS-Related Coronavirus 2
Isolate hCoV-19/USA/VA-FBCH_675/2021 (Lineage AY4.2; Delta Variant)
|
BEI Level 3
|
June
2022
|
|
NR-54980
|
Modified pαH Vector Containing the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein
Middle East Respiratory Syndrome Coronavirus
|
BEI Level 1
|
June
2022
|
|
NR-54978
|
Modified pαH Vector Containing the Human Coronavirus, HKU1 Spike Glycoprotein
Human Coronavirus
|
BEI Level 1
|
June
2022
|
|
NR-56781
|
SARS-Related Coronavirus 2
Isolate hCoV-19/USA/NY-MSHSPSP-PV56475/2022 (Lineage BA.2.12.1;
Omicron Variant)
|
BEI Level 3
|
June
2022
|
|
NR-56699
|
SARS-Related Coronavirus 2
Isolate hCoV-19/France/PAC-IHUMI-6070/2022 p2 (Lineage AY.4 plus Omicron; XD Variant)
|
BEI Level 3
|
June
2022
|
|
NR-54979
|
Modified pαH Vector Containing the Human Coronavirus, OC43 Spike Glycoprotein
Human Coronavirus
|
BEI Level 1
|
May
2022
|
|
NR-56695
|
SARS-Related Coronavirus 2
Isolate hCoV-19/France/PAC-IHUMI-6070/2022 (Lineage AY.4 plus omicron; XD Variant)
|
BEI Level 3
|
May
2022
|
|
NR-55303
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP2F2 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55302
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP2E7 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55301
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP2C7 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55300
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP2C2 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55299
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP1F2 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55298
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP1E6 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55297
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP1D10 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55296
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP1C3 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NR-55295
|
Monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Clone 2TP1B11 (produced in vitro)
SARS-Related Coronavirus 2
|
BEI Level 1
|
May
2022
|
|
NRH-21747
|
Pooled Human Serum Sample, Moderna Vaccine
|
BEI Level 2
|
May
2022
|